Dec 21,2023

Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis– Related Diabetes

Cystic fibrosis–related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis and adds significant morbidity and treatment burden. The study evaluated the safety and efficacy of automated insulin delivery with the iLet bionic pancreas (BP) in adults with CFRD in a single-center, open-label, random-order, crossover trial. Twenty participants with CFRD were assigned in random order to 14 days each on the BP or their usual care (UC). No restrictions were placed on diet or activity. The primary outcome was the percent time sensor-measured glucose was in target range 70–180 mg/dL on days 3–14 of each arm, and key secondary outcomes included mean continuous glucose monitoring (CGM) glucose and the percent time sensor-measured glucose was in hypoglycemic range <54 mg/dL. Results showed that TIR was significantly higher in the BP arm than the UC arm. There was no significant difference in percent time with sensor-measured glucose <54 mg/dL, although self-reported symptomatic hypoglycemia episodes were higher during the BP arm than the UC arm. Adults with CFRD had improved glucose control without an increase in CGM-measured hypoglycemia with the BP compared with their UC, suggesting that this may be an important therapeutic option for this patient population.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 20,2023

Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence

Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. This study aims to assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D.The researchers conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. They included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D. CGM reduced HbA1c and glycemic medication effect score, reduced user satisfaction, and increased the risk of adverse events. isCGM reduced HbA1c by ?0.31%, increased user satisfaction, improved CGM metrics, and increased the risk of adverse events. Accordingly, both CGM and isCGM demonstrated a reduction in HbA1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.

CLINICAL STUDY

#cgm

#bgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2023

Dexcom G7 is now connected to the Tandem t:slim X2 Insulin Pump

DexCom announced the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM system. Tandem will email instructions to all in-warranty t:slim X2 users in the United States to offer the option to add the new feature free of charge via remote software update. Tandem t:slim X2 pumps pre-loaded with Dexcom G7 integration are now shipping to new customers. Starting on 6th of December, Dexcom G7 sensors compatible with the t:slim X2 pump are available through Durable Medical Equipment (DME) distributors, with pharmacy availability launching in early January 2024.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 07,2023

Beta Bionics Announces the Nationwide Launch of the iLet Bionic Pancreas with Dexcom G7 CGM System

Beta Bionics announced the nationwide launch of the iLet Bionic Pancreas automated insulin delivery system with the Dexcom G7 Continuous Glucose Monitoring (CGM) System planned for December 18, 2023. Beta Bionics’ flagship product, the iLet Bionic Pancreas, is an autonomous insulin delivery system that streamlines diabetes management and reduces the burden on patients and physicians. The only input required to get started is the user’s weight. When iLet users “GO BIONIC” with their diabetes management, there’s no carb counting or calculating insulin corrections throughout the day.D excom G7 features an all-in-one sensor and transmitter and a 30-minute warmup time when starting a new sensor. This iLet Bionic Pancreas firmware update will allow users to select Dexcom G7 or Dexcom G6 CGMs, or switch back and forth, depending on their supplies.

COLLABORATION PARTNERSHIP

#connected device

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2023

Stakeholder Insights on rtCGM in T2D Population Health Management

The article explores the evolving landscape of type 2 diabetes (T2D) management within population health, with a specific focus on the underutilized potential of continuous glucose monitoring (CGM) technology, particularly real-time CGM (rtCGM). Sponsored by Dexcom, Inc Medical Affairs, the leading payer and health system stakeholders emphasize recent evidence supporting the integration of rtCGM in T2D population health programs. Highlighting studies such as the MOBILE randomized controlled trial and a Kaiser Permanente Northern California retrospective analysis, the article underscores the benefits of rtCGM, including significant reductions in HbA1c levels and resource utilization. The article concludes by advocating for the incorporation of rtCGM into comprehensive T2D population health initiatives, acknowledging its positive impact on outcomes, resource utilization, and member satisfaction.

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 30,2023

CGMs: A Game-Changer for Sports Nutrition, as Explained by Dr. Andrew Jagim of Mayo Clinic Health System

Nutrisense registered dietitian nutritionist Heather Davis talks with Dr. Andrew Jagim of Mayo Clinic Health System about how to find the best sports nutrition advice, the role of CGMs in athletic performance, and what exciting research projects are on his radar for the future. The interview explores the use of Continuous Glucose Monitors (CGMs) in athletes, acknowledging their potential benefits in optimizing feeding strategies and timing. Additionally, Dr. Jagim reflects on a study indicating the positive impact of regular consultations with sports dietitians on athletes' dietary habits. Future research plans include a monitoring study with a wrestling team, integrating biomarkers and CGMs, as well as initiatives supporting the unique nutritional needs of firefighters

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 30,2023

Digital Diabetes Management Market to Hit USD 22.47 Billion by 2030

The Digital Diabetes Management Market, as per the research publisher, was valued at approximately USD 12.053 billion in 2022, and it is projected to achieve a CAGR of 8.1% during the forecast period of 2023-2030, reaching an estimated size of USD 22.47 billion by 2030. The advent of artificial intelligence (AI) and machine learning in diabetes management has further bolstered the capabilities of these digital tools, enabling more accurate predictive analytics and personalized treatment plans.

#cgm

#insulin pen

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 27,2023

Safety and Efficacy of Sustained Automated Insulin Delivery Compared With Sensor and Pump Therapy in Adults With Type 1 Diabetes at High Risk for Hypoglycemia: A Randomized Controlled Trial

The objective of this study is to assess the safety and efficacy of automated insulin delivery (AID) in adults with type 1 diabetes (T1D) at high risk for hypoglycemia. Participants were 72 adults with T1D who used an insulin pump with Clarke Hypoglycemia Perception Awareness scale score >3 and/or had severe hypoglycemia during the previous 6 months confirmed by time below range of at least 5% during 2 weeks of blinded CGM. Parallel-arm, randomized trial (2:1) of AID (Tandem t:slim ×2 with Control-IQ technology) versus CGM sensor and pump therapy for 12 weeks. The primary outcome was TBR change from baseline. An optional 12-week extension with AID was offered to all participants. Compared with the sensor and pump (S&P), AID resulted in significant reduction of TBR by 3.7%; an 8.6% increase in TIR; and a 5.3% decrease in time above range. Mean sensor glucose reading remained similar in the AID and Sensor & Pump groups. These results show that in adults with T1D at high risk for hypoglycemia, AID reduced the risk for hypoglycemia more than twofold, as quantified by TBR, while improving TIR and reducing hyperglycemia.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 27,2023 TOP STORY

Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-analysis of Outpatient Randomized Controlled Trials

The glycemic control of automated insulin delivery (AID) systems in outpatient children and adolescents with type 1 diabetes (T1D) has not been systematically evaluated. To evaluate the efficacy and safety of AID systems in children and adolescents in outpatient settings, this meta analysis looks at randomized controlled trials that compared AID systems with conventional insulin therapy in outpatient children and adolescents with T1D and reported continuous glucose monitoring outcomes. Twenty-five trials (1,345 participants) were included in the meta-analysis. AID systems were associated with an increased percentage of TIR. The favorable effect was consistent whether AID was used over 3 months or 6 months. AID systems had a favorable effect on the proportion of time below range (TBR) compared with control treatment.

CLINICAL STUDY

#closed loop

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 25,2023 TOP STORY

Digital health application integrating wearable data and behavioral patterns improves metabolic health

The study explores the effectiveness of the remote programfrom January AI, utilizing continuous glucose monitoring (FreeStyle Libre CGM) and wearables (HR monitor (Apple Watch or Fitbit)) to provide lifestyle recommendations for preventing Type 2 Diabetes (T2D). The program enrolled 2,217 participants with varying glucose levels over 28 days, incorporating CGM data, food intake, physical activity, and wearables information through a smartphone app. The app offered daily insights and personalized recommendations based on user preferences and observed glycemic patterns. Significant improvements in hyperglycemia, glucose variability, and hypoglycemia were observed, particularly in non-diabetic individuals. Body weight decreased across all groups, and healthy eating habits improved, indicating that integrating behavior logging, CGM data, and lifestyle recommendations through a mobile app can enhance metabolic health in both nondiabetic and T2D individuals, serving as a valuable tool for T2D prevention and treatment.

CLINICAL STUDY

#cgm

#mobile app

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM